淋巴结阳性前列腺癌的放疗:2019年澳大利亚与新西兰放射肿瘤泌尿生殖组推荐
该推荐由澳大利亚与新西兰放射肿瘤泌尿生殖组(FROGG)基于文献回顾制定,针对临床或病理淋巴结阳性前列腺癌的影像学检查、放疗靶区与剂量以及雄激素剥夺治疗提出循证建议,旨在规范因新型影像技术和高危手术增加而更早发现的区域淋巴结病变的诊疗。
要点
- FROGG基于文献回顾制定淋巴结阳性前列腺癌的循证推荐。
- 推荐涵盖影像技术、放疗靶区与剂量及雄激素剥夺治疗的使用。
- 新型影像技术使区域淋巴结病变更早被发现,为潜在治愈性治疗提供窗口。
核心结论
- FROGG制定了关于临床和病理淋巴结阳性前列腺癌适当检查与管理的循证推荐。
研究设计与样本
- FROGG在2017年研讨会识别管理差异后,回顾文献并制定推荐。
主要发现
- 淋巴结阳性前列腺癌的管理高度可变,区域和全身治疗选择均存在。
- PSMA-PET和MRI等新型影像技术及高危前列腺癌手术的增加,使区域淋巴结病变检出率更高、分期更早。
- 放疗的最佳靶区与剂量以及伴随全身治疗的时机和持续时间仍不确定。
关键数值与推荐
- 推荐涵盖影像技术、放疗靶区和剂量以及雄激素剥夺治疗的使用。
临床怎么用
- 临床医生可参考该推荐对临床或病理淋巴结阳性前列腺癌进行影像学检查、放疗靶区与剂量设定及雄激素剥夺治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The management of node-positive prostate cancer is highly variable, with both locoregional and systemic treatment options available. With the increasing use of novel imaging techniques such as PSMA-PET and MRI, combined with the increasing use of surgery for high-risk prostate cancer, clinical and pathological regional nodal disease is being detected at a higher rate and at an earlier stage than previously. This creates a window for a potentially curative management approach. The role of radiotherapy including optimal radiation target volumes and dose, as well as the timing and duration of accompanying systemic therapy remains uncertain. At a workshop in 2017, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified variations in the management of node-positive prostate cancer identified on primary staging or on histopathology at radical prostatectomy. FROGG reviewed the literature and developed a set of evidence-based recommendations on the appropriate investigation and management of clinically and pathologically node-positive prostate cancer. These recommendations encompass imaging techniques, radiation treatment target volumes and doses, as well as the use of androgen deprivation therapy.
引用
- Lieng H, Kneebone A, Hayden AJ, et al. Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. Radiother Oncol. 2019. PMID: 31177044. doi:10.1016/j.radonc.2019.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。